Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

174.21 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,367
Open 174.21
Bid (Size) 175.45 (1)
Ask (Size) 175.77 (1)
Prev. Close 174.21
Today's Range 174.21 - 174.21
52wk Range 140.68 - 181.16
Shares Outstanding 2,628,679,824
Dividend Yield 2.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now
This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety? 
Via The Motley Fool
Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism
Jim Cramer says Trump creates a "nightmare" for Kenvue after linking Tylenol to autism. Learn why KVUE stock is plunging amid lawsuit fears. 
Via Benzinga
Topics Government Lawsuit

Performance

YTD
+21.0%
+21.0%
1 Month
-2.4%
-2.4%
3 Month
+15.1%
+15.1%
6 Month
+6.7%
+6.7%
1 Year
+6.7%
+6.7%

More News

Read More
Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check?
Via Stocktwits
Topics Government
Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish
Via Stocktwits
Topics Government
U.S. Government Shutdown Looms: A Guide for Investors Navigating Political and Economic Uncertainty
Via MarketMinute
Topics Bonds Economy
Kenvue Stock Sinks To Record Low As Trump To Reportedly Link Tylenol Use To Autism
Via Talk Markets
Topics Government
The Enduring Appeal of Dividend Aristocrats: A Beacon of Stability in Turbulent Markets
Via MarketMinute
Topics ETFs Economy Energy
The Unyielding Power of Dividends: A Blueprint for Enduring Wealth
Via MarketMinute
Topics Retirement Supply Chain
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism
Via Stocktwits
Topics Government
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Ben & Jerry's Co-Founder Resigns In Protest As Politics Continue To Influence Corporate Exits
Via Benzinga
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson Confronts the End of its Talc Legacy with Multi-Billion Dollar Settlements
Via MarketMinute
Topics Bankruptcy Death Lawsuit
P&G's Q3 2025: Sales Miss Overshadows Earnings Beat Amidst Global Headwinds
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Via MarketMinute
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Via MarketMinute
Topics Artificial Intelligence Economy Government
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Via MarketMinute
Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients
Via Benzinga
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?
Via Investor's Business Daily
Recent Report Shows That Rep. Thomas Kean Bought Up to $45K Worth of Amcor Stock
Via Benzinga
8 Dividend Growth Stocks Every Investor Should Consider
Via The Motley Fool
Topics Artificial Intelligence Economy
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
Via Benzinga
Intuitive Surgical: A Steady Hand in a Storm of AI Hype?
Via MarketMinute
Topics Artificial Intelligence Supply Chain

Frequently Asked Questions

Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded.
What exchange does Johnson & Johnson trade on?
Johnson & Johnson trades on the New York Stock Exchange
What is the ticker symbol for Johnson & Johnson?
The ticker symbol for Johnson & Johnson is JNJ on the New York Stock Exchange
What is the current price of Johnson & Johnson?
The current price of Johnson & Johnson is 174.21
When was Johnson & Johnson last traded?
The last trade of Johnson & Johnson was at 09/22/25 07:00 PM ET
What is the market capitalization of Johnson & Johnson?
The market capitalization of Johnson & Johnson is 457.94B
How many shares of Johnson & Johnson are outstanding?
Johnson & Johnson has 458B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.